Jazz Pharmaceuticals Plc (JAZZ)

$108.79

+2.34

(+2.2%)▲

Market is closed - opens 7 PM, 16 Sep 2024

Performance

  • $106.77
    $108.82
    $108.79
    downward going graph

    1.86%

    Downside

    Day's Volatility :1.88%

    Upside

    0.02%

    downward going graph
  • $99.06
    $137.39
    $108.79
    downward going graph

    8.94%

    Downside

    52 Weeks Volatility :27.9%

    Upside

    20.81%

    downward going graph

Returns

PeriodJazz Pharmaceuticals PlcSector (Health Care)Index (Russel 2000)
3 Months
-5.55%
6.8%
0.0%
6 Months
-9.61%
6.4%
0.0%
1 Year
-20.63%
17.3%
0.0%
3 Years
-21.08%
17.7%
-21.1%

Highlights

Market Capitalization
6.6B
Book Value
$60.94
Earnings Per Share (EPS)
5.79
PE Ratio
18.16
PEG Ratio
0.8
Wall Street Target Price
175.56
Profit Margin
10.1%
Operating Margin TTM
19.48%
Return On Assets TTM
4.29%
Return On Equity TTM
10.84%
Revenue TTM
3.9B
Revenue Per Share TTM
62.29
Quarterly Revenue Growth YOY
6.9%
Gross Profit TTM
3.4B
EBITDA
1.4B
Diluted Eps TTM
5.79
Quarterly Earnings Growth YOY
0.64
EPS Estimate Current Year
19.59
EPS Estimate Next Year
21.59
EPS Estimate Current Quarter
4.77
EPS Estimate Next Quarter
5.22

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 25 Wall street analysts offering stock ratings for Jazz Pharmaceuticals Plc(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
20
20
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 61.38%

Current $108.79
Target $175.56

Company Financials

FY18Y/Y Change
Revenue
1.9B
↑ 16.82%
Net Income
447.1M
↓ 8.35%
Net Profit Margin
23.64%
↓ 6.5%
FY19Y/Y Change
Revenue
2.2B
↑ 14.32%
Net Income
523.4M
↑ 17.06%
Net Profit Margin
24.21%
↑ 0.57%
FY20Y/Y Change
Revenue
2.4B
↑ 9.34%
Net Income
238.6M
↓ 54.41%
Net Profit Margin
10.1%
↓ 14.11%
FY21Y/Y Change
Revenue
3.1B
↑ 30.91%
Net Income
-329.0M
↓ 237.86%
Net Profit Margin
-10.63%
↓ 20.73%
FY22Y/Y Change
Revenue
3.7B
↑ 18.26%
Net Income
-214.1M
↓ 34.9%
Net Profit Margin
-5.85%
↑ 4.78%
FY23Y/Y Change
Revenue
3.8B
↑ 4.78%
Net Income
414.8M
↓ 293.72%
Net Profit Margin
10.82%
↑ 16.67%
Q1 FY23Q/Q Change
Revenue
892.8M
↓ 8.16%
Net Income
69.4M
↓ 128.93%
Net Profit Margin
7.78%
↑ 32.46%
Q2 FY23Q/Q Change
Revenue
957.3M
↑ 7.22%
Net Income
104.4M
↑ 50.44%
Net Profit Margin
10.91%
↑ 3.13%
Q3 FY23Q/Q Change
Revenue
972.1M
↑ 1.55%
Net Income
146.8M
↑ 40.58%
Net Profit Margin
15.1%
↑ 4.19%
Q4 FY23Q/Q Change
Revenue
1.0B
↑ 4.09%
Net Income
94.2M
↓ 35.87%
Net Profit Margin
9.3%
↓ 5.8%
Q1 FY24Q/Q Change
Revenue
902.0M
↓ 10.87%
Net Income
-14.6M
↓ 115.53%
Net Profit Margin
-1.62%
↓ 10.92%
Q2 FY24Q/Q Change
Revenue
1.0B
↑ 13.51%
Net Income
168.6M
↓ 1253.15%
Net Profit Margin
16.46%
↑ 18.08%
FY18Y/Y Change
Total Assets
5.2B
↑ 1.56%
Total Liabilities
2.4B
↑ 1.47%
FY19Y/Y Change
Total Assets
5.5B
↑ 6.45%
Total Liabilities
2.4B
↓ 0.74%
FY20Y/Y Change
Total Assets
6.5B
↑ 18.0%
Total Liabilities
2.9B
↑ 18.46%
FY21Y/Y Change
Total Assets
12.3B
↑ 88.17%
Total Liabilities
8.3B
↑ 189.74%
FY22Y/Y Change
Total Assets
10.8B
↓ 11.9%
Total Liabilities
7.7B
↓ 7.01%
FY23Y/Y Change
Total Assets
11.4B
↑ 5.15%
Total Liabilities
7.7B
↓ 1.2%
Q1 FY23Q/Q Change
Total Assets
11.0B
↑ 1.96%
Total Liabilities
7.7B
↓ 0.48%
Q2 FY23Q/Q Change
Total Assets
11.3B
↑ 1.93%
Total Liabilities
7.7B
↑ 0.3%
Q3 FY23Q/Q Change
Total Assets
11.2B
↓ 0.5%
Total Liabilities
7.7B
↓ 0.26%
Q4 FY23Q/Q Change
Total Assets
11.4B
↑ 1.69%
Total Liabilities
7.7B
↓ 0.76%
Q1 FY24Q/Q Change
Total Assets
11.3B
↓ 0.58%
Total Liabilities
7.6B
↓ 0.34%
Q2 FY24Q/Q Change
Total Assets
11.4B
↑ 0.31%
Total Liabilities
7.6B
↓ 0.41%
FY18Y/Y Change
Operating Cash Flow
798.9M
↑ 15.27%
Investing Cash Flow
-394.5M
↑ 46.68%
Financing Cash Flow
-479.1M
↑ 17.11%
FY19Y/Y Change
Operating Cash Flow
776.4M
↓ 2.82%
Investing Cash Flow
-155.3M
↓ 60.63%
Financing Cash Flow
-293.7M
↓ 38.69%
FY20Y/Y Change
Operating Cash Flow
899.6M
↑ 15.87%
Investing Cash Flow
-1.0B
↑ 548.85%
Financing Cash Flow
528.1M
↓ 279.77%
FY21Y/Y Change
Operating Cash Flow
778.5M
↓ 13.47%
Investing Cash Flow
-5.2B
↑ 417.25%
Financing Cash Flow
4.0B
↑ 651.89%
FY22Y/Y Change
Operating Cash Flow
1.3B
↑ 63.39%
Investing Cash Flow
-446.2M
↓ 91.44%
Financing Cash Flow
-529.5M
↓ 113.34%
Q1 FY23Q/Q Change
Operating Cash Flow
320.7M
↓ 6.22%
Investing Cash Flow
-4.8M
↓ 98.51%
Financing Cash Flow
-29.8M
↓ 252.01%
Q2 FY23Q/Q Change
Operating Cash Flow
296.8M
↓ 7.47%
Investing Cash Flow
-85.7M
↑ 1678.08%
Financing Cash Flow
-96.7M
↑ 224.52%
Q3 FY23Q/Q Change
Operating Cash Flow
307.2M
↑ 3.51%
Investing Cash Flow
-174.3M
↑ 103.29%
Financing Cash Flow
-78.5M
↓ 18.8%

Technicals Summary

Sell

Neutral

Buy

Jazz Pharmaceuticals Plc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc
-4.68%
-9.61%
-20.63%
-21.08%
-18.99%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.53%
20.61%
40.93%
82.08%
313.49%
Novo Nordisk A/s
Novo Nordisk A/s
2.31%
2.37%
41.89%
174.22%
452.16%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-2.2%
76.34%
35.57%
40.87%
212.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.37%
15.84%
38.0%
150.97%
173.61%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc
18.16
18.16
0.8
19.59
0.11
0.04
NA
60.94
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.21
30.21
1.55
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
45.38
45.38
2.06
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc
Buy
$6.6B
-18.99%
18.16
10.1%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$125.3B
313.49%
30.21
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$576.2B
452.16%
45.38
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$33.6B
212.74%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.5B
173.61%
32.84
-4.74%

Insights on Jazz Pharmaceuticals Plc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 901.98M → 1.02B (in $), with an average increase of 11.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -14.61M → 168.56M (in $), with an average increase of 108.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 41.9% return, outperforming this stock by 62.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 174.2% return, outperforming this stock by 195.3%

Institutional Holdings

  • Vanguard Group Inc

    10.24%

  • BlackRock Inc

    9.95%

  • LSV Asset Management

    4.02%

  • Capital World Investors

    3.27%

  • State Street Corp

    3.27%

  • Pacer Advisors, INC.

    2.95%

Company Information

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Organization
Jazz Pharmaceuticals Plc
Employees
2800
CEO
Mr. Bruce C. Cozadd
Industry
Health Technology

Discover More

FAQs